Abstract library

49 results for "Vella".
#2739 Epigenetic Landscape of Pancreatic Neuro-Endocrine Tumors Reveals Distinct Cells of Origin and Means of Tumor Progression
Introduction: Pancreatic Neuroendocrine Tumors (PanNETs) arise from cells of the Islets of Langerhans. The majority of PanNETs are non-functional and their cell of origin cannot be defined analysing specific hormone production. Cell of origin assessment has proven importance to identify risk factors, prevent tumour development, and tailor treatment in many malignancies. Recent data on super-enhancer signatures has suggested a potential origin of PanNET from α- or β-cells. We and others have shown that distinct epigenetic profiles assessed by DNA methylation (DNAme) characterize genomic and prognostic groups of PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Annunziata Di Domenico
#2740 Long-Term Complete Response in Metastatic Poorly-Differentiated Neuroendocrine Rectal Carcinoma with Multimodal Approach. A Case Report
Introduction: Rectal neuroendocrine carcinomas (NEC) are extremely rare and account for less than 1% of colorectal malignancies.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Medical Doctor Pietro Maria Lombardi
#2932 Evaluation of Nurse Preferences between the Lanreotide Autogel New Syringe and Octreotide Long-Acting Release Syringe: An International Simulated Use Study (PRESTO)
Introduction: A new lanreotide autogel/depot (LAN) syringe was developed based on feedback from a human factors study to improve user experience.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Xuan Mai Truong Thanh
#3017 Patient and Healthcare Practitioner Perspectives of Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
Introduction: Somatostatin analogs (SSAs) are used to treat acromegaly and neuroendocrine tumors (NETs). Two first-generation SSAs, octreotide and lanreotide, are available to patients (pts).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Costello Medical
Authors: Feuilly M, Jenni E, Cella D, ...
#2703 Carcinoid Heart Disease: A Retrospective Study and a Multidisciplinary Proposal of a New Algorithm
Introduction: Development of carcinoid heart disease (CHD) is the major negative prognostic factor in patients with the carcinoid syndrome. The only effective treatment is valve replacement. However, the selection of candidates and determination of optimal timing remain unclear. Considerable variability in local treatment strategies exist
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Aicha Bengueddach
#2862 Concurrent Metastatic Pulmonary Neuroendocrine Tumor and Pituitary Macroadenoma
Introduction: The coexistence of a sellar mass in a patient with a neuroendocrine tumor, while rare, can paint the clinical picture of either a genetic syndrome, most notably multiple endocrine neoplasia syndrome type 1(MEN1) or pituitary metastasis recently more frequent probably due to the longer survival of cancer patients.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD, PhD, Lecture Carmen Sorina Martin
#43 Relationship between neuroendocrine tumor-related symptoms and RAND-36 health-related quality of life scores
Introduction: Neuroendocrine tumors (NETs) can secrete hormones that cause flushing and diarrhea (carcinoid syndrome) and disrupt health-related quality of life (HRQL).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Beaumont J L, Liu Z, Choi S, Yao J C, ...
#44 Somatostatin analogue therapy and RAND-36 health-related quality of life scores in patients with neuroendocrine tumors
Introduction: Somatostatin analogues (SSAs) are used in patients with neuroendocrine tumors (NETs) for the management of carcinoid syndrome and/or delay of disease progression.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Yao J C, Beaumont J L, Choi S, Cella D, ...
#45 Neuroendocrine tumor disease state and RAND-36 health-related quality of life scores
Introduction: Health-related quality of life (HRQL) can be disrupted in patients with malignancies.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Phan A, Beaumont J L, Liu Z, Choi S, ...
#76 Role of contrast-enhanced ultrasonography in the differential diagnosis of the pancreatic and hepatic lesions
Introduction: Contrast-enhanced ultrasonography (CEUS) is a new promising tool for the characterization of pancreatic lesions. This technique allows for highlighting the micro-vascularization of a lesion, especially with the use of second generation contrast media, characterized by harmonic responses at low acoustic pressures. Pancreatic endocrine tumors (PET)s were reported to have a peculiar behavior at CEUS, consisting of a higher enhancement compared to normal pancreas in the arterial phase and a rapid washout.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Francesco Milone